

SUB C1  
B1

comprising a nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration *in vitro*.

SUB C2  
B2

19. (Amended) A recombinant virus according to claim 16, wherein said virus further comprises a second nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration.

SUB C3  
B3

22. (Amended) A method of inhibiting toxicity in cultured neuronal cells comprising administering to said cells a nucleic acid encoding a mutated form of p53 which antagonizes wild-type p53-mediated neuronal cell degeneration *in vitro*.

### REMARKS

#### **I. Status of the Claims**

Claims 16-22, 25, and 26 are pending in this application and have all been rejected by the Office. With this response, claims 16, 19, and 22 have been amended. Claims 23, 24, and 27-31 have been withdrawn from further consideration by the Office as drawn to a non-elected invention. Office Action, pages 2-3. Applicants have filed a separate petition requesting review of the restriction requirement and await a decision concerning the matter. In the meantime, Applicants have amended the remaining claims to remove the non-elected subject matter to fully respond to the present Office Action. Should Applicants receive a favorable review of their petition, the non-elected subject matter will be reinserted into the claims. As requested by the Examiner, Applicants enclose a separate copy of all pending claims.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com